Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Nanomi B V maintains a focused prosecution presence in the Biotechnology & Pharmaceuticals technology area. There is 1 pending office action currently active, which is assigned to 1 distinct art unit. This indicates a specific technical niche for the company's current filings.
KETCHAM, KAREN A is the 1 distinct examiner for this portfolio and holds the 1 busiest examiner pending action. Since all prosecution activity is funneled through a single examiner, the review process is highly centralized. This structure places the entirety of the current docket under the discretion of one individual.
Practitioners should focus on the specific procedural and technical preferences of the assigned examiner. Because the entire pending portfolio is subject to a single individual's review, the strategy must be precisely calibrated to that examiner's standards. This high level of concentration simplifies docket management but increases the importance of each filing.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KETCHAM, KAREN A | 1 | 19.6% | +37.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16936383 | SUSTAINED RELEASE TREPROSTINIL-COMPOUND MICROPARTICLE COMPOSITIONS | KETCHAM, KAREN A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16936383 | SUSTAINED RELEASE TREPROSTINIL-COMPOUND MICROPARTICLE COMPOSITIONS | KETCHAM, KAREN A | — |
| Art Unit | Apps |
|---|---|
| 1614 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 16936383 | SUSTAINED RELEASE TREPROSTINIL-COMPOUND MICROPARTICLE COMPOSITIONS | KETCHAM, KAREN A | 1614 | §103 | Non-Final OA | — | Pending | Jul 22, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNanomi B V has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Karen A Ketcham has the most, with 1 of Nanomi B V's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
